This retrospective chart review study will describe the history of patients with retinal disease with macular edema to whom OZURDEX® (dexamethasone intravitreal implant) is administered, and assess treatment patterns and visual outcomes. OZURDEX® was previously administered according to general clinical practice.
Study Type
OBSERVATIONAL
Enrollment
101
Dexamethasone Intravitreal Implant (OZURDEX®) previously administered according to general clinical practice.
Unnamed facility
Québec, Quebec, Canada
Peak Mean Change From Baseline in Best Corrected Visual Acuity (BCVA)
BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). The peak mean change in BCVA was calculated using the most improved number of lines read correctly between 2 and 26 weeks following the last available injection of OZURDEX® - the number of lines read correctly at Baseline. A positive change from Baseline indicated improvement.
Time frame: Baseline, 2 to 26 weeks (wks) following last injection (up to 6.5 months)
Peak Mean Change From Baseline in Central Retinal Thickness (CRT)
Optical Coherence Tomography (OCT), a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina, was performed in the study eye. The peak mean change was the maximum change from Baseline in CRT at 2 to 26 weeks following the last available injection of OZURDEX®. A negative change from Baseline indicated improvement.
Time frame: Baseline, 2 to 26 weeks following last injection (up to 6.5 months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.